MYC and B-cell non-Hodgkin lymphoma: In line with this hypothesis, researchers recently found that genetic or pharmacological inhibition of sumoylation diminishes the survival of MYC-positive B-cell lymphoma cells in culture, while also impairing disease maintenance in mouse xenograft models [172].